Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 7, 2013, Pages 736-742

  Agrawal, Ashish ^a   Matthay, Michael A ^b,c   Kangelaris, Kirsten N ^b   Stein, John ^a   Chu, Jeffrey C ^c   Imp, Brandon M ^b   Cortez, Alfredo ^a   Abbott, Jason ^c   Liu, Kathleen D ^b   Calfee, Carolyn S ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Anesthesia ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCSF Medical Center at Parnassus   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Angiopoietin 2; Lung Injury Prediction Score; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; INTERLEUKIN 8; VON WILLEBRAND FACTOR;

ACUTE LUNG INJURY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

ACUTE LUNG INJURY; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CRITICAL ILLNESS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 84875865632     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201208-1460OC     Document Type: Article

References (44)

1. ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.NEngl J Med 2004;351:327-336.
2. ARDS Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561-568.
3. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, et al. Lung Open Ventilation Study I. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008;299:637-645.
4. Mercat A, Richard JC, Vielle B, Jaber S, Osman D, Diehl JL, Lefrant JY, Prat G, Richecoeur J, Nieszkowska A, et al. Expiratory Pressure Study Group. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008;299:646-655.
5. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr., Hite RD, Harabin AL. National Heart Lung Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-2575.
6. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
7. National Heart, Lung, and Blood Institute. Clinical Center for a Clinical Trials Research Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network), NHLBI-HR-14-03. 2012 [accessed 2012 May 31]. Available from: http://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-HR-14-03/listing.html
8. Gajic O, Dabbagh O, Park PK, Adesanya A, Chang SY, Hou P, Anderson H III, Hoth JJ, Mikkelsen ME, Gentile NT, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 2011;183:462-470.
9. Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, Kojicic M, Kashyap R, Thakur S, Thakur L, Herasevich V, Malinchoc M, Gajic O. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J 2011;37:604-609.
10. Kor DJ, Warner DO, Alsara A, Fernandez-Perez ER, Malinchoc M, Kashyap R, Li G, Gajic O. Derivation and diagnostic accuracy of the surgical lung injury prediction model. Anesthesiology 2011;115:117-128.
11. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010;137: 288-296.
12. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, Matthay MA. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011;39:711-717.
13. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, Zhang X, Matthay MA, Ware LB, Homer RJ, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006;12:1286-1293.
14. Barnett N, Ware LB. Biomarkers in acute lung injury-marking forward progress. Crit Care Clin 2011;27:661-683.
15. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3:e46.
16. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of tie2 signaling in the endothelium. Mol Cell Biol 2009;29:2011-2022.
17. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, Sukhatme VP. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008;29:656-661.
18. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008;63:903-909.
19. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012;40:1731-1737.
20. Fremont RD, Koyama T, Calfee CS, Wu W, Dossett LA, Bossert FR, Mitchell D, Wickersham N, Bernard GR, Matthay MA, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 2010;68:1121-1127.
21. Meyer NJ, Li M, Feng R, Bradfield J, Gallop R, Bellamy S, Fuchs BD, Lanken PN, Albelda SM, Rushefski M, et al. Angpt2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 2011; 183:1344-1353.
22. Ong T, McClintock DE, Kallet RH, Ware LB, Matthay MA, Liu KD. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med 2010;38:1845-1851.
23. Cepkova M, Brady S, Sapru A, Matthay MA, Church G. Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care 2006; 10:R126.
24. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008;12:R41.
25. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP, Network NARDSCT. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005;33:1-6, discussion 230-232.
26. Moss M, Gillespie MK, Ackerson L, Moore FA, Moore EE, Parsons PE. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. Crit Care Med 1996;24:1782-1786.
27. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001;29:2325-2331.
28. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004;170:766-772.
29. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, Mednick G, Matthay ZA, Matthay MA. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006;173:1008-1015.
30. Calfee CS, Budev MM, Matthay MA, Church G, Brady S, Uchida T, Ishizaka A, Lara A, Ranes JL, deCamp MM, et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007;26:675-680.
31. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, Matthay MA, Network NA. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008;63: 1083-1089.
32. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990;86:474-480.
33. Liu X, Chen Q, Shi S, Shi Z, Lin R, Tan L, Yu J, Shu Q, Fang X. Plasma sRAGE enables prediction of acute lung injury following cardiac surgery in children. Crit Care 2012;16:R91.
34. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Liu KD, Calfee CS. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Presented at the National Clinical and Translational Sciences Predoctoral Programs Meeting. May 6-8, Rochester, MN.
35. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Liu KD, Calfee CS. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Presented at the UCSF Inter-School Research and Scholarly Activity Festival. May 3-4, San Francisco, CA.
36. Agrawal A, Matthay MA, Liu KD, Calfee CS. Plasma levels of the receptor for advanced glycation end products (RAGE) are elevated in early acute lung injury but not in severe sepsis [abstract]. Am J Respir Crit Care Med 2012;185:A6815.
37. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
38. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-2533.
39. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172; discussion 207-212.
40. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011;39:702-710.
41. Spragg RG, Bernard GR, Checkley W, Curtis JR, Gajic O, Guyatt G, Hall J, Israel E, Jain M, Needham DM, et al. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med 2010; 181:1121-1127.
42. Rainer TH, Lam PK, Wong EM, Cocks RA. Derivation of a prediction rule for post-traumatic acute lung injury. Resuscitation 1999;42:187-196.
43. David S, Park JK, Meurs M, Zijlstra JG, Koenecke C, Schrimpf C, Shushakova N, Gueler F, Haller H, Kumpers P. Acute administration of recombinant angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 2011; 55:251-259.
44. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev 1993;7:52-62.